Embed Size (px)
Citation preview
CURRICULUM VITAE OF
LISSINDA DU PLESSIS
1. General information
Title : Dr.
Name : Lissinda
Initials : L.H.
Surname : Du Plessis
Maiden name : Boshoff
Identification number : 810103 0027 088
Current organisation : North-West University
Citizenship : South Africa
Date of birth : 3 January 1981
Gender : Female
Race : White
Highest qualification : PhD (Biochemistry)
Title of thesis : The effect of different ozone
concentrations on white blood cell
energy homeostasis
2. Contact details Organisation where based : North-West University
Department : Pharmaceutics
Primary organisation which funds
salary :
North-West University
Faculty : Faculty of Health Sciences, School of Pharmacy
Work telephone number : +27(0)18 299 4246
Work fax number : +27(0)18 299 2251
Mobile number : +27(0) 82 805 4743
Website address : http://www.puk.ac.za/fakulteite/gesond/nfa9.2
E-mail address : [email protected]
Home address : Bizet avenue 19, Potchefstroom, 2531
Postal address : P.O. Box 19865, Noordbrug, 2522
3. Current employment
Positions : Associate Professor
Full Time : Yes
Type : Permanent
Appointment date : January 2013
Organisation : North-West University, Potchefstroom Campus
Sector : Higher Education Sector
4. Work postal address
Organisation Address : Private Bag X6001
North-West University
School of Pharmacy, Subject group
Pharmaceutics
Potchefstroom
2520
Province or State : North-West Province
Country : Republic of South Africa
5. Work physical address
Organisation Address : Department Pharmaceutics
Room G15, Building G02
Hoffmann Street
2520
Province or State : North-West Province
Country : Republic of South Africa
6. Qualifications
Degree/Diploma : Doctor of Philosophy PhD
Field of study : Biochemistry
Institution : North-West University, Potchefstroom campus
Year obtained : 2007
Degree/Diploma : Master of Science M.Sc Cum Laude
Field of study : Physiology (Membrane and electrophysiology)
Institution : North-West University, Potchefstroom campus
Year obtained : 2005
Distinction : Yes
Degree/Diploma : Baccalaureus Scientiae Honnours B.Sc Honns Cum
Laude
Field of study : Physiology
Institution : Potchefstroom University for Christian Higher
Education
Year obtained : 2003
Degree/Diploma : Baccalaureus Scientiae B.Sc
Field of study : Health Sciences
Institution : Potchefstroom University for Christian Higher
Education
Year obtained : 2002
7. Employment history
Position Organisation Period
Junior Lecturer (Part time) North-West University, Potchefstroom
campus, Physiology
2002-02 - 2004-09
Laboratory Technician North-West University, Potchefstroom
campus, Biochemistry
2004-10 - 2006-10
Post Doctoral Fellow North-West University, Potchefstroom
campus, Unit for Drug Research and
Development
2006-11 - 2008-01
Senior Subject Specialist North-West University, Potchefstroom
campus, Unit for Drug Research and
2008-02 - 2010-06
Development
Senior Lecturer North-West University, Potchefstroom
campus, Pharmaceutics
2010-07 - 2012-12
Associate Professor North-West University, Potchefstroom
campus, Pharmaceutics
2013-01 - current
8. Research expertise
8.1 Scientific domain
Health and Medical Sciences
8.2 Broad scientific field
Pharmaceutical and Toxicological Sciences
8.3 Main research field
Toxicology, Cell Biology, Pharmaceutics
8.4 Fields of specialisation
Drug delivery systems
Drug delivery for parasite and neglected diseases
Mechanisms of drug delivery
Oxidative stress
Mechanism of Toxicology
Molecular Pharmaceutics and Toxicology
9. Teaching expertise
Teachings are in the fields of Physiology, Zoology (2001-2004) and Pharmaceutics (2010-current):
Introduction to Physiology (FLGX111) First year BSc Practical 2001
Zoology Lower invertebrates (DRKN111) First year BSc Practical 2001
Zoology Higher invertebrates and chordata (DRKN123) First year BSc practical 2001
Endocrinology (FLGX211) Second year BSc Practical 2002
Metabolism (FLGX212) Second year BSc Practical 2002
Gastrointestinal physiology (FLGX121) First year BSc Theory 2003
Membrane and electrophysiology A (FLGX611) Honns BSc Theory 2004
Membrane and electrophysiology B (FLGX626) Honns BSc Theory 2004
Lecturer for 4th year Pharmacy students, FMSG 422, Biotechnological and innovative
pharmaceutical dosage forms, Theory and practical. 2010-current
Lecturer for 2nd year Pharmacy students, FBCG 211, Pharmaceutical and Clinical
Biochemistry, Theory and practical 2014-current
10. Academic Research
10.1 Own academic Research
10.1.1 Research project in physiology (Honns); Title: Pore forming toxins in the venom of
Opistophthalmus wahlbergii. Primary focus: Isolation and characterizing of components in
Southern African scorpion venom responsible for pore formation in cell membranes (2002).
Supervisor: K. Dyason.
10.1.2 Research project in physiology (M. Sc.); Title: The electrophysiological effects of fractions
isolated from the venom of Parabuthus granulatus on cardiac Ca2+ channels; Primary focus:
Isolation and characterizing of components in Southern African scorpion venom,
responsible for an agonistic effect on calcium channels in heart muscle (2003-2004).
Supervisor: K. Dyason; Co-supervisor: J.L. du Plessis.
10.1.3 Research project in biochemistry (PhD); Title: The effect of different ozone concentrations
on white blood cell energy homeostasis; Primary focus: Evaluation of the effectiveness of
ozone autohemotherapy by using molecular, oxidative stress and antioxidant enzyme
analysis (2005-2007). Promotor: H.F Kotzé; Co-promotor: F.H. van der Westhuizen.
10.1.4 Post-Doctoral Research project in Pharmaceutics, Innovation Fund Project T60042:
Optimisation of drug delivery for tuberculosis, malaria and paediatric Aids. Primary focus:
The possible enhancement of the efficacy of antimalarial drugs with Pheroid™ technology
(2006-2008). Under the Guidance of Prof A.F. Kotzé.
10.1.5 Peptide drug delivery using lipid and polymer based delivery systems; Primary focus:
Delivery of peptide drugs using Pheroid technology and trimethyl chitosan (2009-2011).
10.1.6 Drug delivery for neglected diseases, NRF Thukthuka grant TTK20110812000024249;
Primary focus: Optimize the delivery of both existing and new drug molecules with the use
of selected lipid-based and polymeric drug delivery systems for the treatment of malaria
(2012-2014).
10.1.7 Formulation, characterization and in vivo bioavailability and efficacy evaluation of N-
trimethyl chitosan chloride nanoparticles for the antimalarial drugs, dapsone and proguinal,
MRC grant; Primary focus: Formulate and characterize N-trimethyl chitosan chloride
nanoparticles in combination with the antimalarial combination treatment dapsone and
proguinal (2012-2014).
10.1.8 Molecular toxicology Primary focus: Evaluation of the molecular toxic effects of excipients
and nanoparticulate drug delivery systems (2014-current).
10.2 Interdepartmental collaboration
10.2.1 Research projects in mitochondrial complex I deficiencies, antioxidant supplements,
evaluating of oxidative stress, antioxidant defence systems and antioxidant capacity in
human subjects (2005-2010). F.H. van der Westhuizen, H.F Kotzé (Department of
Biochemistry).
10.2.2 Investigation into the possible toxic effects of occupational exposure to harmful chemical
substances (2008-current). J.L. du Plessis, P.J. Laubscher, F.C. Eloff, M.N. van Aarde, A.
Franken (School of Physiology, Nutrition and Consumer Sciences, Department Physiology,
Occupational hygiene).
10.2.3 Investigation into the oxidative stress effects of metabolytes of hereditarily tirosinemia
type 1 (2010-current). Department of Biochemistry. Prof P.J. Pretorius.
10.2.4 Investigation into the cellular and molecular toxicology of newly synthesised chemical
entities. Collaboration with Pharmaceutical chemistry, Prof G Terreblanche and Prof David
N’Da. (2009-current)
10.2.5 Investigation into Rotavirus structural proteins and their effect on innate immunity (2013-
2014). Collaboration with Prof Albie van Dijk, Department Biochemistry.
10.2.6 Collaboration with Dr. Mulunda Mwanza, Department of Agriculture, Mafikeng Campus,
North-West University (2013-current).
10.3 National research collaboration
10.3.1 Investigation into the transfection efficiency of malaria parasites using. Pheroid™
technology. T van Brummelen and H. Hoppe. CSIR Biosciences.
10.3.2 Pharmacokinetic/Pharmacodynamic (PK/PD) drug studies. L. Wiesner, L. Cape Town
Bioanalytical Services, University of Cape Town.
10.4 International research collaboration
10.4.1 Innovation fund project T90020 Investigation into drug resistance reversal of antimalarials
using Pheroid™ technology. R. Brun & S.Wittlin. Swiss Tropical Institute, Basel,
Switzerland.
10.4.2 MRC Flagship, Development to the Clinical Phase of Oxidant and Redox Drug Combinations
for Treatment of Malaria, TB and Related Diseases.
11. Student supervision record 11.1 Masters student supervision record - Supervisor
11.1.1 Slabbert, C. 2007-2008. Evaluation and validation of methods to determine parasitemia in
malaria cell cultures (Completed).
11.1.2 Van Huyssteen, E. 2008-2009. Efficacy enhancement of the antimalarial drugs, mefloquine
and artesunate with Pheroid™ technology (Completed).
11.1.3 Van Niekerk, A(E.C.). 2008-2009. In vitro antimalarial efficacy enhancement of selected
antibiotics with Pheroid™ technology (Completed).
11.1.4 Scholtz, J. 2009-2010. Preparation, stability and in vitro evaluation of liposomes containing
amodiaquine (Completed).
11.1.5 Nieuwoudt, S. 2009-2010. Preparation, stability and in vitro evaluation of liposomes
containing chloroquine (Completed).
11.1.6 Van der Merwe, A. 2010-2012. Development and evaluation of an oral fixed-dose triple
combination dosage form for artesunate, dapsone and proguanil (Completed).
11.1.7 Du Toit, L. 2012-2014. Hemocompatibility and immunogenicity of N-trimethyl chitosan
chloride nanoparticles (Completed).
11.1.8 Jacobs, G. 2014-. In vitro evaluation of the cytotoxic, antibacterial and antioxidant properties
of selected chitosan derivatives and melittin (Current).
11.2 Masters student supervision record – Co-Supervisor
11.2.1 Langley, N. 2006-2007. A preclinical evaluation of the possible enhancement of the efficacy
of anti-malaria drugs by Pheroid™ technology (Completed).
11.2.2 Odendaal, R.W. 2008-2009. Efficacy enhancement of the antimalarial drugs, mefloquine and
artemether with Pheroid™ technology (Completed).
11.2.3 Van der Linde, E. 2009-2010. The metabolic profile of phenylbutyric acid in vitro and in vivo
(Completed).
11.2.4 Chinembiri, T. 2011-2013. The effect of Pheroid technology on 5-fluoranicil treatment of skin
cancer (Completed).
11.2.5 Govender, K. 2010-2013. In vitro and In vivo Evaluation of Pheroid Technology applied to
Lumefantrine and Piperaquine (Completed) In Collaboration with UCT.
11.2.6 Marais. E. 2011-2013. Permeation of rat and porcine jejunum by insulin released from
Eudragit® L100/Trimethyl chitosan chloride (TMC) microspheres (Completed).
11.3 Masters student supervision record – Assistant Supervisor
11.3.1 Van Niekerk, L. 2007-2008. PheroidTM technology for the topical delivery of Insulin growth 1
(IGF-1), Keratinocyte growth (KGF) and vascular endothelial growth factor (VGF)
(Completed).
11.3.2 Van der Merwe, H. 2006-2008. Evaluation and validation of in vitro assays to determine cell
viability for HIV/AIDS experimentations with Pheroid™ technolgy (Completed).
11.3.3 Campbell, B. 2007-2010. PheroidTM technology for the topical treatment of Hyper-pigmented
skin (Completed).
11.4 PhD student supervision record - Promotor
11.4.1 Slabbert, C. 2009-2011. Formulation, characterization and cellular toxicity of lipid-based drug
delivery systems for mefloquine (Completed).
11.4.2 Booysen, L. 2007-2013. The in vitro and in vivo pharmacokinetic parameters of polylactic-co-
glycolic acid nanoparticles encapsulating anti-tuberculosis drugs (Completed).
11.4.3 Marais, E.B. 2013-. Formulation and characterization of solid lipid nanoparticles containing
lumefantrine for the treatment of malaria (Current).
11.4.4 Lewies, A. 2014-. Formulation and evaluation of solid lipid nanoparticles containing
structurally modified melittin for topical delivery (Current)
11.5 PhD student supervision record – Co-Promotor
11.5.1 Steyn, J.D. 2007-2009. Novel artemisinin derivatives with Pheroid™ technology for malaria
treatment (Completed).
11.5.2 Langley, N. 2008-2011. The effect of PheroidTM technology on the antimalarial efficacy and
bioavailability of chloroquine and amodiaquine (Completed).
11.5.3 Chinimbiri, T. 2014-. The potential of Carissa edulis and Withania somnifera crude extracts as
topical anti-melanoma agents (Current).
11.6 Post Doctoral Fellows
11.6.1 Mohammed, F. 2012-2013. Chemical synthesis and formulation of TMC nanoparticles
conjugated with silver for the treatment of neglected diseases.
11.6.2 Wentzel, J. 2014-2016. Immunogenecity of selected nanoparticulate systems.
12. Scientific publications
Publications are in the fields of Toxicology, Cell Biology and Pharmaceutics.
12.1 Elgar, D., Du Plessis, L.H. and Du Plessis, J.L. 2006. Cysteine-free peptides in scorpion venom:
Geographical distribution, structure-function relationship and mode of action. African
Journal of Biotechnology. 5(25):2495-2502, December 2006.
12.2 Du Plessis, L.H., Van der Westhuizen, F.H. and Kotze, H.F. 2007. The effect of blood
ozonation on mitochondrial function and apoptosis of peripheral blood mononuclear cells in
the presence and absence of antioxidants. African Journal of Biotechnology. 6(15):1763-
1769, August 2007.
12.3 Du Plessis, L.H., Van der Westhuizen, F.H. and Kotze, H.F. 2008. The protective effect of
plasma antioxidants during ozone autohemotherapy. African Journal of Biotechnology,
7(14):2472-2477, July 2008.
12.4 Du Plessis, L.H., Elgar, D. and Du Plessis, J.L. 2008. Southern African scorpion toxins: an
overview. Toxicon, 51:1-9.
12.5 Keretetse, G.S., Laubscher, P.J., Du Plessis, J.L., Pretorius, P.J., Van der Westhuizen, F.H., van
Deventer, E., Van Dyk, E., Eloff, F.C., Van Aarde, M.N. and Du Plessis, L.H. 2008. DNA damage
and repair detected by the comet assay in lymphocytes of African petrol attendants: A pilot
study. Annals of occupational hygiene, 52(7):653-662.
12.6 Du Plessis, L.H., Lubbe, J., Strauss, T., Kotze, A.F. 2010. Enhancement of nasal and intestinal
calcitonin delivery by the novel PheroidTM fatty acid based delivery system, and by N-
trimethyl chitosan chloride. International Journal of Pharmaceutics, 385:181–186.
12.7 Du Plessis, L.H., Laubscher, P.J., Jooste, J., du Plessis, J.L., Franken, A., van Aarde, M.N. and
Eloff, F.C. 2010. Flow cytometric analysis of the oxidative status in human peripheral blood
mononuclear cells of workers exposed to welding fumes. Journal of Occupational and
Environmental Hygiene, 7:367-374.
12.8 Du Plessis, L.H., Kotze, A.F. and Junginger, H.E. 2010. Nasal and rectal delivery of insulin with
chitosan and N-trimethyl chitosan chloride. Drug Delivery, Aug;17(6):399-407.
12.9 Steyn, J.D., du Plessis, L.H. and Kotzé, A.F. 2010. Nasal delivery of recombinant human
growth hormone: in vivo evaluation with Pheroid™ technology and N-trimethyl chitosan
chloride. Journal of Pharmacy and Pharmaceutical Sciences,13(2):263-273.
12.10 Reinecke, F. Levanets, O., Louw, R., Du Plessis, L.H., Nijtmans, L., Smeitink, J.A.M. and Van
der Westhuizen, F.H. 2011. Mitochondrial DNA replication and OXPHOS gene transcription
show weak responsiveness to Rieske protein knockdown in 143B cells Biochimie, 93:758-
765.
12.11 Slabbert C., du Plessis L.H., Kotzé A.F. 2011. Evaluation of the physical properties and
stability of two lipid drug delivery systems containing mefloquine. International Journal of
Pharmaceutics, 409:209–215.
12.12 Steyn, J.D., Wiesner, L., du Plessis, L.H., Grobler, A.F., Smith, P.J., Chan, W.C., Haynes, R.K.
and Kotzé, A.F. 2011. Absorption of the novel artemisinin derivatives artemisone and
artemiside: Potential application of Pheroid™ technology. International Journal of
Pharmaceutics. 414(1-2):260-266.
12.13 Gouws, C., Steyn, J.D., du Plessis, L.H., Hamman, J.H. 2012. Combination therapy of Western
drugs and herbal medicines: recent advances in understanding interactions involving
metabolism and efflux. Expert Opinion On Drug Metabolism and Toxicology. 8:973-984.
12.14 Du Plessis, L.H., Maritz, M., Van Niekerk, A., Kotze, A.F. 2012. In vitro activity of Pheroid™
vesicles containing antibiotics against Plasmodium falciparum. Journal of Antibiotics. 65:609-
614.
12.15 Booysen, L.L., Kalombo, L., Brooks, E., Hansen, R., Gilliland J., Gruppo, V., Lungenhofer, P.,
Semete-Makokotlela, B., Swai, H.S., Kotze, A.F., Lenaerts, A. du Plessis, L.H. 2013. In vivo/in
vitro pharmacokinetic and pharmacodynamic study of spray-dried poly-(DL-lactic-co-glycolic)
acid nanoparticles encapsulating rifampicin and isoniazid. International Journal of
Pharmaceutics. 444:10-17.
12.16 Buys, G.M., du Plessis, L.H., Marais, A.F., Kotze, A.F. Hamman, J.H. 2013. Direct compression
of chitosan: Process and formulation factors to improve powder flow and tablet
performance. Current Drug Delivery. 10:348-356.
12.17 Marais, E., Hamman, J.H., du Plessis, L.H., Lemmer, R., Steenekamp, J. 2013. Eudragit L100/N-
trimethyl chitosan chloride microspheres for oral insulin delivery. Molecules. 7;18(6):6734-47.
12.18 du Plessis LH, Helena C, van Huysteen E, Wiesner L, Kotzé AF 2014. Formulation and
evaluation of Pheroid vesicles containing mefloquine for the treatment of malaria. Journal of
Pharmacy and Pharmacology. 66(1):14-22
12.19 du Plessis, L.H. & Hamman, J.H. 2014. In vitro evaluation of the cytotoxic and apoptogenic
properties of aloe leaf materials. Drug and Chemical Toxicology. 37(2):169-177.
12. 20 du Plessis, L.H., Marais, E.B., Mohammed, F., Kotze A.F. Applications of lipid based
formulation technologies in the delivery of biotechnology-based therapeutics. In Press
Current Pharmaceutical Biotechnology.
12.21 Joubert J.P., Smit F.J., du Plessis L., Smith P.J., N'Da D.D. 2014. Synthesis and in vitro
biological evaluation of aminoacridines and artemisinin-acridine hybrids. European Journal
of Pharmaceutical Sciences, 2;56:16-27.
12.22 Chiembiri, T., du Plessis, L.H., Gerber, M, Hamman, J.H., du Plessis, J. 2014. Review of natural
compounds for skin cancer treatment. Molecules, 19, 11679-11721.
12.23 Tawona N. Chinembiri, Minja Gerber, Lissinda du Plessis, Jan L. du Preez and Jeanetta du
Plessis. 2014. Topical delivery of 5-fluorouracil from novel Pheroid™ formulations and the in
vitro efficacy against human melanoma. Submitted to Drug Development Research.
12.24 Govender, K., Du Plessis, L.H., Wiesner, L. Development and Validation of a LC-MS/MS
Method for the Quantification of Lumefantrine in Mouse Whole Blood and Plasma.
Submitted to Pharmaceutical Methods.
12.25 Mohammed, F., du Plessis, L.H. Chitosan mediated biofabrication. Submitted to European
Polymer Journal.
13. Books/chapters in books
13.1 du Plessis, J.L., du Plessis, L.H. 2010. Different Methods of Collecting Scorpion Venom. In
Venoms: Sources, Toxicity and Therapeutic uses. Series: Advances in Biology and Medicine.
Jonas Gjersoe and Simen Hundstad (ed). Nova Science Publishers, Inc, Hauppauge, NY, USA.
ISBN : 978-1-60876-448-8. pp. 231-245.
13.2 du Plessis, L.H. 2013. Drug delivery: Rectal Route. In Encyclopaedia of Pharmaceutical
Science and Technology. July 1, 2013 by CRC Press Content:4296 Pages Editor(s):James
Swarbrick ISBN 9781841848198
13.3 du Plessis, L.H. & Kotze, A.F. Pheroid™ Vesicles and Microsponges for Nasal Delivery of
Biopharmaceuticals. In Mucosal Delivery of Biopharmaceuticals. Biology, Challenges and
Strategies das Neves, José, Sarmento, Bruno (Eds.). Springer. 2014, XIX, 601 p. 333-344.
13.4 Mohammed, F., du Plessis, L.H., Arfin, T. X-ray analysis of metal oxide-metal core shell
particles. In X-ray diffraction, Structure, principles and applications. Kaimin Shih editior.
Nova Science Publishers, Inc, Hauppauge, NY, USA, ISBN: 978-1-62808-593-8.
14. Published Conference Proceedings
14.1 Article published in the Proceedings of the 13th Biennial Congress of the International
Society for Free Radical Research (SFRR), August 15-19, 2006, Davos, Switzerland. Title: The
effect of different ozone concentrations on white blood cell energy homeostasis. L.H. du
Plessis, F.H. van der Westhuizen, H.F. Kotze.*
14.2 Abstract published in Tropical Medicine and International Health, 14, suppl 2, 127,
September 2009. 6th European Congress on Tropical Medicine and International Health,
Verona Italy, 6-10 September 2009. Title: Enhancement of the in vitro antimalarial efficacy
of atemisinins and quinolines by Pheroid™ vesicles. L.H. du Plessis, N. Langley, C. Slabbert,
R.W. Odendaal, E. van Huysteen, A.F. Kotze*
14.3 Abstract published in Tropical Medicine and International Health, 14, suppl 2, 128,
September 2009. 6th European Congress on Tropical Medicine and International Health,
Verona Italy, 6-10 September 2009. Title: Assessment of the in vitro efficacy of selected
artemisinin derivatives in combination with the Pheroid™ drug delivery system. A.F. Kotzé,
L.H. du Plessis, J.D. Steyn, A.F. Grobler, R.K. Haynes.*
14.4 Abstract published in Journal of Pharmacy and Pharmacology, 62(6):789. Perspectives in
Percutaneous Penetration, 12th International Conference, 7–10 April, 2010, La Grande
Motte, France. Title: Topical delivery of selected growth factors. Van Niekerk, L., Campbell,
B., Gerber, M., Du Plessis, L.H., Du Plessis, J.*
15. Significant Conference Outputs
15.1 National Conferences
15.1.1 Poster presentation at the 31st annual meeting of the Physiological Society of Southern
Africa (PSSA), Potchefstroom, South Africa, 18-20 September 2003. Title: The agonistic
effect of Parabuthus granulatus venom on cardiac and nerve cells. Winner of Poster Prize,
best Poster Presentation. du Plessis, L.H., du Plessis, J.L. & Dyason, K.
15.1.2 Poster presentation at the 20th SASBMB conference, Pietermaritzburg, South Africa, 2-5 July
2006. Title: The effect of different ozone concentrations on leukocyte energy homeostasis.
du Plessis, L.H., van der Westhuizen, F.H. & Kotze, H.F.
15.1.3 Co-chair of Lecture session, metabolism and physiological biochemistry at the 20th SASBMB
conference, Pietermartizburg, South Africa, 2-5 July 2006.
15.1.4 Poster presentation at the 28th annual conference of the Academy of Pharmaceutical
Sciences, Langebaan, South Africa, 4-7 September 2007. Title: An in vitro evaluation of
PheroidTM microsponges for anti-malarial drug delivery. Slabbert, C., Du Plessis, L. & Kotze, A.
15.1.5 Oral presentation at the 28th annual conference of the Academy of Pharmaceutical Sciences,
Langebaan, South Africa, 4-7 September 2007. Title: Preclinical evaluation of the possible
enhancement of the efficacy of anti-malaria drugs by PheroidTM technology. Langley N., Du
Plessis L. & Kotze, A.
15.1.6 Poster presented at the 29th Annual Conference of the Academy of Pharmaceutical Sciences,
Rustenburg, South Africa, 22- 6 September 2008. Title: Enhancement of the In vitro Efficacy
of Chloroquine with Pheroid™ Technology. Langley N., Du Plessis L.H., Liebenberg W. &
Kotze, A.F.
15.1.7 Poster presented at the 29th Annual Conference of the Academy of Pharmaceutical Sciences,
, Rustenburg, South Africa, 22 - 26 September 2008. Title: Alternative methods to determine
malaria parasitemia levels for drug efficacy tests. Slabbert, C., Du Plessis, L.H. & Kotze, A.F.
15.1.8 Oral presentation at the Joint Workshop on Nanotechnology, Drug delivery and Poverty
related diseases., CSIR Pretoria, South-Africa, May 2009. Title: The use of alternative
formulation strategies to enhance the efficacy of antimalarials. Grobler, A., du Plessis, L.H.,
Rautenbach, M., Langley, N., Steyn, J.D., Haynes, R.K., Liebenberg, W. & Kotze, A.F.
15.1.9 Oral presentation at the 31st Annual Conference of the Academy of Pharmaceutical
Sciences. University of Limpopo, Turfloop campus, South Africa, 14-17 September 2010.
Title: The metabolic profile of phenylbutyric acid and its antioxidant capacity in vervet
monkeys and Hela cells. van der Linde, W.J., Terreblanche, G., du Plessis, L.H., Mienie, L.J.,
Bergh, J.J. Runner-up to young scientist competition.
15.1.10 Poster presented at the 33rd Academy of Pharmaceutical Sciences of South Africa (APSSA)
conference 2012, Rhodes University, 12-15 September 2012. Title: Eudragit L100/N-
trimethyl chitosan chloride microspheres for oral insulin delivery. Marais, E., Hamman, J.H.,
du Plessis, L.H., Lemmer, R., Steenekamp, J.
15.1.11 Poster presented at the ICPA/APSSA/SAAPI Three's Company Pharmacy Conference 2013, 4 -
6 October 2013 Venue: Lagoon Beach Hotel, Milnerton, South Africa. Title: In vitro activity of
Pheroid™ vesicles containing antibiotics against Plasmodium falciparum. Lissinda H. Du
Plessis, Anel C. van Niekerk, Marlene M. Maritz, Awie F. Kotzé
15.1.12 Poster presented at the ICPA/APSSA/SAAPI Three's Company Pharmacy Conference 2013, 4 -
6 October 2013 Venue: Lagoon Beach Hotel, Milnerton, South Africa. Title: Formulation and
in vivo efficacy of dapsone and proguanil in trimethyl chitosan microparticles. Lissinda du
Plessis, Jaco van Heerden, Jan Steenekamp, Awie Kotze.
15.2 International Conferences
15.2.1 Poster presentation at the 13th biennial meeting of the Free Radical Research International,
Davos, Switzerland, August 2006. Title: The effect of different ozone concentrations on
white blood cell energy homeostasis. du Plessis, L.H., van der Westhuizen, F.H. & Kotze, H.F.
15.2.2 Oral presentation at IOHA 7th International Scientific Conference Taipei, Taiwan, 18-22
February 2008. Title: DNA damage and repair detected by the comet assay in lymphocytes of
African petrol attendants. Keretetse, G., Laubscher, P.J., du Plessis, J.L., Pretorius, P., van
Deventer, E., Eloff, F.C., van Aarde, M.N., van Dyk, E., & du Plessis, L.H.
15.2.3 Poster presented at the 1st International Conference on Drug Design & Discovery, February
3-6, Dubai, UAE. 2008. Title: An in vitro evaluation of the enhancement in efficacy of anti-
malarial drugs by Pheroid™ technology. Langley, N., Grobler, A., Du Plessis, L., Kotze, A. &
Liebenberg, W.
15.2.4 Poster presented at the Pathogenesis and Control of Emerging Infections and Drug-Resistant
Organisms, Keystone Symposia Global Health Series, Bangkok, Thailand, 22-27 October
2008. Title: Enhancement of the in vitro efficacy of chloroquine with Pheroid™ technology.
Langley, N., Du Plessis, L., Liebenberg, W. & Kotze, A.*
15.2.5 Poster presented at the Drug Discovery for Protozoan Parasites, Keystone Symposia Global
Health Series, Breckenridge, Colorado, 22-26 March 2009. Title: Enhancement of the in vitro
efficacy of mefloquine and artesunate with Pheroid technology. Du Plessis, L.H., Slabbert, C.,
Steyn, J.D., van Huyssteen, E., Kotzé, A.F.
15.2.6 Invited Lecture presented at the International Conference on Pharmaceutical and
Pharmacological Sciences (ICPPS), North-West University, Potchefstroom South Africa, 23-26
September 2009. Title: Topical and/or transdermal growth factors in cosmetics. Gerber, M.,
Campbell, B., van Niekerk, L., Grobler, A., du Plessis, L.H. & du Plessis, J.
15.2.7 Poster presented at the International Conference on Pharmaceutical and Pharmacological
Sciences (ICPPS), North-West University, Potchefstroom South Africa, 23-26 September
2009) Title: An in vitro evaluation of triclosan in combination with Pheroid technology for
antimalarial treatment. du Plessis, L.H., Steyn, J.D. & Kotze, A.F.
15.2.8 Poster presented at the International Conference on Pharmaceutical and Pharmacological
Sciences (ICPPS), North-West University, Potchefstroom South Africa, 23-26 September
2009. Title: In vitro antimalarial efficacy enhancement of mefloquine and artemether with
Pheroid technology. Odendaal, R.W., du Plessis, L.H., Kotze, A.F.
15.2.9 Poster presented at the International Conference on Pharmaceutical and Pharmacological
Sciences (ICPPS), North-West University, Potchefstroom South Africa, 23-26 September
2009. Title: Enhancement of the in vitro efficacy of chloroquine with Pheroid technology on
multi-drug resistant malaria parasites. Langley N., Du Plessis L. & Kotze, A.
15.2.10 Poster presented at the 6th European Congress on Tropical Medicine and International
Health, Verona Italy, 6-10 September 2009. Title: Enhancement of the in vitro antimalarial
efficacy of artemisinins and quinolines by Pheroid™ vesicles. du Plessis, L.H., Langley, N.,
Slabbert, C., Odendaal, R.W., van Huysteen, E. & Kotze A.F.
15.2.11 Poster presented at the 6th European Congress on Tropical Medicine and International
Health, Verona Italy, 6-10 September 2009. Title: Assessment of the in vitro efficacy of
selected artemisinin derivatives in combination with the Pheroid™ drug delivery system.
Kotzé, A.F., du Plessis, L.H., Steyn, J.D., Grobler, A.F. & Haynes, R.K.
15.2.12 Oral presentation presented at the Controlled Release Society (CRS) annual meeting,
Copenhagen, Denmark, 18-22 July 2009. Title: The use of alternative formulation strategies
to enhance the efficacy of antimalarials. Grobler, A., du Plessis, L.H., Rautenbach, M.,
Langley, N., Steyn, J.D., Haynes, R.K., Liebenberg, W. & Kotze, A.F.
15.2.13 Poster presented at the 7th World Meeting on Pharmaceutics, Biopharmaceutics and
Pharmaceutical Technology, Malta 8-11 March 2010. Title: Size characterisation of Pheroid™
technology and liposomes. Slabbert, C., Nieuwoudt, L.M., du Plessis, L.H. & Kotzé, A.F.
15.2.14 Poster presented at the 7th World Meeting on Pharmaceutics, Biopharmaceutics and
Pharmaceutical Technology, Malta, 8-11 March 2010. Title: Entrapment ability of Pheroid™
technology and liposomes. Nieuwoudt, L.M., Slabbert, C., du Plessis, L.H. & Kotzé, A.F.
15.2.15 Poster presented at the Perspectives in Percutaneous Penetration, 12th International
conference, La Grande Motte, France, 7-10 April 2010. Title: Topical delivery of selected
growth factors. Van Niekerk, L., Campbell, B., Gerber, M., Du Plessis, L.H. & Du Plessis, J.
15.2.16 Poster presented at the 2011 AAPS annual meeting and exposition, Washington DC, USA, 23-27
October 2011. Title: In vitro growth inhibition of chloroquine and amodiaquine against Plasmodium
falciparum with PheroidTM technology. Langley, N., du Plessis, L.H. & Kotze, A.F.
15.2.17 Poster presented at the 2011 AAPS annual meeting and exposition, Washington DC, USA, 23-27
October 2011. Title: In vitro stage specific activity of chloroquine and amodiaquine against
Plasmodium falciparum with PheroidTM technology. Langley, N., du Plessis, L.H. & Kotze, A.F.
15.2.18 Poster presented at the 2011 AAPS annual meeting and exposition, Washington DC, USA, 23-27
October 2011. Title: Preparation, stability and in vitro evaluation of liposomes containing
amodiaquine and chloroquine. du Plessis, L.H., Nieuwoudt, S., Scholtz, J. & Kotze, A.F.
15.2.19 Poster presented at the 2011 AAPS annual meeting and exposition, Washington DC, USA, 23-27
October 2011. Title: The in vitro efficacy and toxicity evaluation of mefloquine loaded lipid based drug
delivery systems for treatmetn of malaria. Slabbert, C., du Plessis, L.H., & Kotze, A.F.
15.2.20 Oral presentation at the 6th ICPPS, Durban, South Africa, 25-27 September 2011. Title: A
bioavailability study of lumefantrine in mice; evaluating the application of PheroidTM formulation.
Govender, K., Wiesner, L., Du Plessis, L.H. & Smith, P.
15.2.21 Poster presentation at the 3rd Conference on Innovation in Drug Delivery, Pisa Italy, 22 September
2013- 25 September 2013. Title: In vitro activity of Pheroid™ vesicles containing antibiotics against
Plasmodium falciparum. Lissinda H. Du Plessis, Anel C. van Niekerk, Marlene M. Maritz, Awie F. Kotzé
15.2.22 Poster presentation at the 3rd Conference on Innovation in Drug Delivery, Pisa Italy, 22 September
2013- 25 September 2013. Title: Formulation and in vivo efficacy of dapsone and proguanil in
trimethyl chitosan microparticles. Lissinda du Plessis, Jaco van Heerden, Jan Steenekamp, Awie Kotze.
15.2.23 Poster presented at the 5th FIP Pharmaceutical Sciences World Congress (PSWC) Melbourne,
Australia 13-16 April 2014. Title: Hemocompatibility of N-trimethyl Chitosan Chloride Nanoparticles.
Lizl du Toit, Jan H. Steenekamp, Lissinda H. du Plessis.
16. Research Grants Received DST-IF R874 000 2008
NWU- R&D R 20 000 2008
NWU- R&D R30 000 2009
DST-IF R 679 971 2009 NWU- R&D R 40 000 2010 NWU strategic funds Ultra centrifuge R 800 000 2010 NWU- R&D R 30 000 2011 NWU- R&D R30 000 2012 MRC R 150 000 2012 NRF-Thukthuka R250 000 2012 NWU-R&D R20 000 2013 NRF-Thukthuka R434 000 2013 NWU Strategic funds for specialized infrastructure FACSVerse R2 456 700 2013 NWU-R&D R20 000 2014 MRC R150 000 2014
DST-IF – Department of Science and Technology, Innovation Fund; NWU- R&D – North-West University, Unit for Drug Research and Development; NWU strategic funds – Strategic funds for equipment; MRC – Medical Research Council.
17. Professional Affiliations
Member of the Physiology Society of Southern Africa (2003-2005).
Member of the South African Society of Biochemistry and Molecular Biology – SASBMB (2005-2011).
International Association for the advancement of Cytometry, (ISAC) 2009-current.
American Association of Pharmaceutical Scientist, (AAPS), 2011-2012.
Member of the Academy of the Pharmaceutical Society of South Africa (PSSA) (2012-current).
International Pharmaceutical Federation (Fip) (2013-current).
Toxicological Society of South Africa (ToxSA) (2014-current).
18. Examiner
18.1 Internal Examiner of Botha, M. 2007. M. Sc. Pharmaceutics. Preclinical evaluation of the
possible enhancement of the efficacy of anti-retroviral drugs by PheroidTM technology.
18.2 Internal Examiner of Maritz, F. 2007. M. Sc. Pharmaceutics. In vivo evaluation of the efficacy
of nasal PheroidTM based calcitonin formulations.
18.3 Internal Examiner of Pretorius, M. 2008. M. Sc. Pharmaceutics. PheroidTM based anti-
malarial formulations HPLC method development and stability studies.
18.4 External Examiner Master of Medical Science (Pharmaceutical Chemistry): “Plasma stability
and protein binding of PCU- peptides.” Student: L Motisa, Student Number: 205505120,
(Department of Pharmaceutical Sciences, University of KwazuluNatal).
18.5 External Examiner PhD in Pharmaceutics Mrs L. Kukati Studies on the applicability of gum
karaya in the design of chronotherapeutic drug delivery system of losartan potassium.
Andrana University, India.
19. Attendances of short courses, workshops and seminars
19.1 Introduction to computers and information systems. 1999.
19.2 Handling of Laboratory animals. 2002.
19.3 Research methodology seminar. 2003.
19.4 PCR seminar. 2005.
19.5 Pipetting short course. 2005.
19.6 BD Biosciences FACSCalibur™ training course. 2006
19.7 GLP/GMP seminar, including Quality assurance. 2007.
19.8 HPLC short Course. 2008.
19.9 Confocal short Course.2009.
19.10 Institutional course for new lecturers (IKND). 2010.
19.11 Academic support services workshop on Introduction to eFundi. 2010
19.12 Academic support services workshop on Cooperative learning. 2011.
19.13 Academic support services workshop on Assessement. 2011.
19.14 Academic support services workshop Big Classes Forum. 2012.
19.15 Academic support services workshop on Education strategies. 2013.
19.16 TOXSA workshop 2014, In vivo and in vitro methods to identify and evaluate chemical health hazards:
establishment of laboratory facilities and provision of training in the Risk Assessment of chemicals in
South Africa.
20. Awards – merit and finacial
20.1 National research foundation (NRF) free standing bursary. 2002.
20.2 National research foundation (NRF) free standing bursary. 2005-2006
20.3 Scholastic awards, undergraduate and post graduate. 2001, 2002, 2004.
20.4 Winner of Poster Prize, best Poster Presentation, 31st annual meeting of the Physiological Society of
Southern Africa (PSSA), Potchefstroom, South Africa, 18-20 September 2003.
20.5 SAIOH, Article of the year, student of the year, Keretetse G. 2009.
20.6 SAIOH, Article of the year, du Plessis et al., 2010.
21. Editorial Boards and Review Committees
21.1 Advisory Board
21.1.1. Advisory board for Advances in Natural and Applied Sciences (ANAS). (1/9/2008-1/9/2012).
21.2 Reviewer
Regular reviewer for the following Journals: African Journal of Biotechnology, Medicinal Research reviews,
Cellular and molecular life sciences, Current drug therapy, The European Journal of Pharmacology, Recent
Patents on Anti-Infective Drug Discovery, International Journal of Pharmaceutics, Journal of Controlled
Release, Current Drug Delivery, AAPS PharmSciTech, Drug Delivery, Journal of Drug Delivery Science and
Technology.
21.3 Internal Committees 21.3.1 Faculty of Health Sciences, Ethics committee.
21.3.2 Faculty of Health Sciences, Research committee.
21.3.3 Faculty of Health Sciences, Faculty Board.
References
Prof. Awie Kotzé
Professor in Pharmaceutics, NWU Potchefstroom campus
Director School of Pharmacy
Supervisor for Post-Doctoral position (Pharmaceutics)
(018) 299 2249.
Prof. Jeanetta du Plessis
Professor in Pharmaceutics, NWU Potchefstroom campus
Director Unit for drug Research and Development
(018) 299 2274.
Dr. Lubbe Wiesner
Cape Town Bioanalytical Services
H50, Old Main Build, Groote Schuur Hospital
Observatory
Phone: +27-83 451 7260
Dr. Gill Enslin
Tswane University of Technology (TUT)
Tel (012) 382 6230.
Prof. Melgaardt de Villiers
University of Wisconsin
Tel: 608-890-0732.
Prof T Govender
University of KwaZulu Natal
Tel: 00 27 31 260 7358/083 326 3195.
